DHR

Danaher Corporation

DHR, USA

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

https://www.danaher.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
DHR
stock
DHR

Danaher Stock (DHR) News Today: BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus ts2.tech

Read more →
DHR
stock
DHR

Wells Fargo Adjusts Price Target for Danaher (DHR) to $240 | DHR Stock News GuruFocus

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$254.2

Analyst Picks

Strong Buy

19

Buy

4

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

46.76

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

3.16

Low 1

High 3

Return on Equity (ROE)

-

Very Low

1.78 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.14 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

22.63 %

Low 5%

High 15%

Debt to Equity

-

High

0.56

Low 1

High 0.3

Investors

* Institutions hold a combined 59.71% of the total shares of Danaher Corporation

1.

Vanguard Group Inc

(8.4868%)

since

2025/06/30

2.

BlackRock Inc

(7.2947%)

since

2025/06/30

3.

State Street Corp

(3.8125%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.826%)

since

2025/07/31

5.

Wellington Management Company LLP

(2.3848%)

since

2025/06/30

6.

T. Rowe Price Associates, Inc.

(2.3205%)

since

2025/06/30

7.

Capital Research & Mgmt Co - Division 3

(2.2967%)

since

2025/06/30

8.

Vanguard 500 Index Investor

(2.2019%)

since

2025/07/31

9.

FMR Inc

(2.0254%)

since

2025/06/30

10.

Geode Capital Management, LLC

(1.9169%)

since

2025/06/30

11.

Morgan Stanley - Brokerage Accounts

(1.5827%)

since

2025/06/30

12.

NORGES BANK

(1.3994%)

since

2025/06/30

13.

Bank of New York Mellon Corp

(1.1745%)

since

2025/06/30

14.

Fidelity 500 Index

(1.1276%)

since

2025/07/31

15.

SPDR® S&P 500® ETF

(1.0753%)

since

2025/08/31

16.

iShares Core S&P 500 ETF

(1.0704%)

since

2025/08/31

17.

Northern Trust Corp

(1.0514%)

since

2025/06/30

18.

JPMorgan Chase & Co

(1.0317%)

since

2025/06/30

19.

T. Rowe Price Investment Management,Inc.

(0.9711%)

since

2025/06/30

20.

Vanguard Dividend Growth Inv

(0.942%)

since

2025/06/30

21.

HHG PLC

(0.9115%)

since

2025/06/30

22.

UBS Asset Mgmt Americas Inc

(0.8889%)

since

2025/06/30

23.

Parnassus Investments LLC

(0.8823%)

since

2025/06/30

24.

Bank of America Corp

(0.8487%)

since

2025/06/30

25.

Vanguard Value Index Inv

(0.7973%)

since

2025/07/31

26.

Goldman Sachs Group Inc

(0.7527%)

since

2025/06/30

27.

Capital Group Wash Mutual Invtrs Comp

(0.7182%)

since

2025/06/30

28.

American Funds Washington Mutual A

(0.7182%)

since

2025/06/30

29.

Generation Investment Management LLP

(0.6935%)

since

2025/06/30

30.

Vanguard Health Care Inv

(0.678%)

since

2025/06/30

31.

Parnassus Core Equity Investor

(0.6499%)

since

2025/07/31

32.

T. Rowe Price Capital Appreciation

(0.6498%)

since

2025/07/31

33.

The Health Care Select Sector SPDR® ETF

(0.6074%)

since

2025/08/31

34.

Vanguard Institutional Index I

(0.5378%)

since

2025/07/31

35.

Vanguard Dividend Appreciation ETF

(0.4801%)

since

2025/07/31

36.

State St S&P 500® Indx SL Cl III

(0.4748%)

since

2025/08/31

37.

Capital Group Investment Co of Amer Comp

(0.3733%)

since

2025/06/30

38.

American Funds Invmt Co of Amer A

(0.3733%)

since

2025/06/30

39.

Six Circles U.S. Unconstrained Equity

(0.3449%)

since

2025/03/31

40.

Vanguard Institutional 500 Index Trust

(0.3397%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(6)
Growth
Moderate Growth(5)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.